Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Aya Shoda is active.

Publication


Featured researches published by Aya Shoda.


Bioorganic & Medicinal Chemistry Letters | 2013

6-(4-Pyridyl)pyrimidin-4(3H)-ones as CNS penetrant glycogen synthase kinase-3β inhibitors.

Fumiaki Uehara; Aya Shoda; Keiichi Aritomo; Kenji Fukunaga; Kazutoshi Watanabe; Ryoichi Ando; Masaki Shinoda; Hiroaki Ueno; Hideo Kubodera; Shinji Sunada; Kenichi Saito; Takahide Kaji; Shoichi Asano; Jun-ichi Eguchi; Satoshi Yuki; Shinji Tanaka; Yukimi Yoneyama

The discovery of a series of 6-(4-pyridyl)pyrimidin-4(3H)-ones derived from a hit compound with low molecular weight and sufficient chemical space is reported. Transformation of substituents led to subnanomolar potent inhibitors with in vivo tau phoshorylation lowering activity.


Bioorganic & Medicinal Chemistry Letters | 2013

2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; A new class of potent, selective and orally active glycogen synthase kinase-3β inhibitors

Kenji Fukunaga; Fumiaki Uehara; Keiichi Aritomo; Aya Shoda; Shinsuke Hiki; Masahiro Okuyama; Yoshihiro Usui; Kazutoshi Watanabe; Koichi Yamakoshi; Toshiyuki Kohara; Tokushi Hanano; Hiroshi Tanaka; Susumu Tsuchiya; Shinji Sunada; Kenichi Saito; Jun-ichi Eguchi; Satoshi Yuki; Shoichi Asano; Shinji Tanaka; Akiko Mori; Keiji Yamagami; Hiroshi Baba; Takashi Horikawa; Masatake Fujimura

A series of 2-(2-phenylmorpholin-4-yl)pyrimidin-4(3H)-ones was synthesized and examined for their inhibitory activity against glycogen synthase kinase-3β (GSK-3β). We found 21, 29 and 30 to possess potent in vitro GSK-3β inhibitory activity with good in vitro PK profiles. 21 demonstrated significant decrease of tau phosphorylation after oral administration in mice and excellent PK profiles.


Archive | 2002

3-substituted-4-pyrimidone derivatives

Fumiaki Uehara; Keiichi Aritomo; Aya Shoda; Shinsuke Hiki; Masahiro Okuyama; Yoshihiro Usui; Mitsuru Ooizumi; Kazutoshi Watanabe


Archive | 2001

2-[nitrogen-heterocyclic]pyrimidone derivatives

Garcia Antonio Almario; Ryoichi Ando; Jonathan Reid Frost; Adrien Tak Li; Aya Shoda


Archive | 2004

2,3,6-trisubstituted-4-pyrimidone derivatives

Kazutoshi Watanabe; Fumiaki Uehara; Shinsuke Hiki; Satoshi Yokoshima; Yoshihiro Usui; Masahiro Okuyama; Aya Shoda; Keiichi Aritomo; Toshiyuki Kohara; Kenji Fukunaga


Archive | 2001

2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives

Garcia Antonio Almario; Ryoichi Ando; Keiichi Aritomo; Jonathan Reid Frost; Adrien Tak Li; Aya Shoda; Fumiaki Uehara; Kazutoshi Watanabe


Archive | 2005

2-amino-3-(alkyl)-pyrimidone derivatives

Antonio Almario Carcia; Ryoichi Ando; Keiichi Arimoto; Fumiaki Uehara; Adrien Tak Li; Aya Shoda; Jonathan Reid Frost; Kazutoshi Watanabe


Archive | 2004

2,3,6-trisubstituierte-4-Pyrimidonderivate

Kazutoshi Watanabe; Fumiaki Uehara; Shinsuke Hiki; Satoshi Yokoshima; Toshiyuki Kohara; Kenji Fukunaka; Yoshihiro Usui; Masahiro Okuyama; Aya Shoda; Keiichi Aritomo


Archive | 2002

DERIVADOS DE PIRIMIDONA DE LA FORMULA (1) O SALES DE LOS MISMOS Y MEDICAMENTOS QUE CONTIENEN DICHOS DERIVADOS COMO INGREDIENTE ACTIVO

Kazutoshi Watanabe; Aya Shoda; Ryoichi Ando; Kenichi Saito; Rie Kawamoto


Archive | 2002

Derives de 3-substitute-4-pyrimidone

Fumiaki Uehara; Keiichi Aritomo; Aya Shoda; Shinsuke Hiki; Masahiro Okuyama; Yoshihiro Usui; Mitsuru Ooizumi; Kazutoshi Watanabe

Collaboration


Dive into the Aya Shoda's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fumiaki Uehara

Mitsubishi Tanabe Pharma

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Shinsuke Hiki

Mitsubishi Tanabe Pharma

View shared research outputs
Top Co-Authors

Avatar

Yoshihiro Usui

Mitsubishi Tanabe Pharma

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge